Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CPS1 | P31327 | 4/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20670508 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4MAPK1HPGDTAAR1 | |
| SCHEMBL10971731 | 0.81 | CYP3A4 (0.53) | ALDH1A1CYP3A4MAPK1HPGDUSP2 | |
| SCHEMBL29664206 | 0.81 | MAOB (0.35) | MAPK1MAOBNPC1RAB9AMAOA | |
| SCHEMBL20670578 | 0.81 | MAOB (0.35) | MAPK1MAOBNPC1RAB9AMAOA | |
| SCHEMBL4480739 | 0.80 | ALDH1A1 (0.44) | ALDH1A1CYP3A4MAPK1HPGDUSP2 | |
| SCHEMBL4487005 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CYP3A4MAPK1HPGDUSP2 | |
| SCHEMBL158153 | 0.78 | TAAR1 (0.56) | ALDH1A1CYP3A4MAPK1TAAR1HDAC1 | |
| SCHEMBL20670887 | 0.77 | KDM4E (0.47) | ALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL29664155 | 0.77 | CES2 (0.47) | SMN1; SMN2HDAC1MAOBHTT | |
| SCHEMBL20670577 | 0.77 | CES2 (0.47) | SMN1; SMN2HDAC1MAOBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4574210-A2 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | The Scripps Research Institute (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4141001-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240343719-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2024-10-17 | — | — | US | disclosed |
| CN-110914262-B | Kappa opioid receptor antagonists and products and methods relating thereto | 斯克里普斯研究所 | 2024-04-05 | — | — | CN | disclosed |
| US-11897873-B2 | Kappa opioid receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4141001-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | The Scripps Research Institute (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3596069-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | ALDH1A1 2192/4885CYP3A4 856/4885MAPK1 813/4885 |
| US-20240343719-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | ALDH1A1 2154/4885CYP3A4 843/4885MAPK1 858/4885 |
| US-11897873-B2 | Kappa opioid receptor antagonists and products and methods related thereto | OPRK1, OPRD1, OPRM1 | ALDH1A1 2159/4885CYP3A4 859/4885MAPK1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.